Evidence map›Paper›PMID 32983253›Full record

ArticleInfectious agents and cancer2020

A study of the mechanism of lncRNA-CR594175 in regulating proliferation and invasion of hepatocellular carcinoma cells in vivo and in vitro.

Quan Liu, Xuxu Yu, Minjie Yang, Xiangke Li, Xuejia Zhai, Yujin Lian, Zhong Chen, Qingxia Fan, Lijie Song, Wencai Li

Abstract read
In one paragraph

Article in Infectious agents and cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Grain-Sized Moxibustion Heightens the AntiTumor Effect of Cyclophosphamide in Hepa1-6 Bearing Mice.Evidence-based complementary and alternative medicine : eCAM · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Quan Liu *Department of Emergency, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052 China.
Xuxu Yu *Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052 China.
Minjie YangDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052 China.
Xiangke LiDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052 China.
Xuejia ZhaiDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052 China.
Yujin LianDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052 China.
Zhong ChenDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052 China.
Qingxia FanDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052 China.
Lijie SongDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052 China.ORCID 0000-0003-0102-2407
Wencai LiDepartment of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052 China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is one of the cancers of highest incidence and mortality worldwide. The proliferation and invasion of tumor cells are the main reason for poor prognosis after HCC surgery. Long non-coding RNA (lncRNA) has been shown to play a key role in the progression of HCC. LncRNA-CR594175 is one of the highly expressed lncRNAs in HCC tumors and their metastatic tumors that we have obtained by the High-throughput screening method.

methodsTo elucidate the role of lncRNA-CR594175 in regulating the proliferation and invasion of human hepatoma cell line, HepG2, we operated through lncRNA-CR594175 silencing to inhibit the progression of HCC, either through in vitro or in vivo experiments.

resultsWe found that lncRNA-CR594175 was lower in adjacent non-cancerous tissues than in primary HCC, and was lower in primary HCC than in its metastasis. Silencing of lncRNA-CR594175 inhibited the proliferation and invasion of HepG2 cells and growth of subcutaneous tumors. The results revealed that lncRNA-CR594175, as a RNA sponge, broke the negative regulation of hsa-miR-142-3p on Catenin, beta-1 (CTNNB1), and once lncRNA-CR594175 was silenced, the hsa-miR142-3p regained its negative regulation on CTNNB1 which can promote HCC progression by activating the wnt pathway.

conclusionsOur present study demonstrated for the first time that lncRNA-CR594175 silencing suppressed proliferation and invasion of HCC cells in vivo and in vitro by restoring the negative regulation of hsa-miR-142-3p on CTNNB1, laying a solid theoretical base for using lncRNA-CR594175 as genetic target therapy for HCC and offering a reasonable explanation for inactivation of miRNA in different tumors or in the tumor at different stages.

Indexed as

Hepatocellular carcinomaHepG2Hsa-miR142-3plncRNAlncRNA-CR594175

Identifiers

PMID32983253
PMCPMC7510120

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.